Clearing the air: Assessing inhaler usage and associated greenhouse gas emissions in a health system.

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Keaton S Smetana, Jake Girardot, Samantha Hopton, Adam Trimble, Beth Eckl, Allegra Wiesler
{"title":"Clearing the air: Assessing inhaler usage and associated greenhouse gas emissions in a health system.","authors":"Keaton S Smetana, Jake Girardot, Samantha Hopton, Adam Trimble, Beth Eckl, Allegra Wiesler","doi":"10.1093/ajhp/zxae384","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The transition from chlorofluorocarbons (CFCs) to hydrofluoroalkanes (HFAs) has significantly reduced the greenhouse gas (GHG) emissions associated with metered-dose inhalers (MDIs). However, HFAs still have a high global warming potential (GWP) compared to other alternatives such as dry powder inhalers (DPIs) and soft mist inhalers (SMIs). This transition has significantly impacted GHG emissions, underscoring a need to evaluate the environmental impact of medication delivery via MDIs.</p><p><strong>Objectives: </strong>This study quantifies the GHG emissions, expressed as carbon dioxide equivalents (CO2e), from the use of HFAs in MDIs within our health system. The healthcare system includes 13 hospitals with over 2,000 staffed beds and approximately 100,000 annual patient admissions. It also examines the broader environmental impacts of the packaging materials associated with these inhalers.</p><p><strong>Methods: </strong>A retrospective analysis of the use of albuterol and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) MDIs over a 1-year period, assessing their CO2e emissions and the environmental impact of their packaging. The total weight of propellant was determined by calculating the difference in canister weight before use and after all contents were expelled.</p><p><strong>Results: </strong>A total of 17,589 albuterol and 20,563 ICS/LABA MDIs were dispensed during the study. The total propellant weight led to CO2e emissions of 212 metric tons (MT) for albuterol MDIs and 506 MT for ICS/LABA MDIs. Including resource use and emissions from inhaler components led to an environmental impact that totaled 213 MT of CO2e for albuterol MDIs and 512.5 MT for ICS/LABA MDIs.</p><p><strong>Conclusion: </strong>Our study emphasizes the necessity of integrating environmental stewardship into healthcare practices. By fostering awareness and initiating discussions on sustainable practices, particularly in the context of pharmacy operations, we can contribute to a more environmentally responsible healthcare system while continuing to meet the clinical needs of our patients.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"e607-e614"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Health-System Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxae384","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The transition from chlorofluorocarbons (CFCs) to hydrofluoroalkanes (HFAs) has significantly reduced the greenhouse gas (GHG) emissions associated with metered-dose inhalers (MDIs). However, HFAs still have a high global warming potential (GWP) compared to other alternatives such as dry powder inhalers (DPIs) and soft mist inhalers (SMIs). This transition has significantly impacted GHG emissions, underscoring a need to evaluate the environmental impact of medication delivery via MDIs.

Objectives: This study quantifies the GHG emissions, expressed as carbon dioxide equivalents (CO2e), from the use of HFAs in MDIs within our health system. The healthcare system includes 13 hospitals with over 2,000 staffed beds and approximately 100,000 annual patient admissions. It also examines the broader environmental impacts of the packaging materials associated with these inhalers.

Methods: A retrospective analysis of the use of albuterol and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) MDIs over a 1-year period, assessing their CO2e emissions and the environmental impact of their packaging. The total weight of propellant was determined by calculating the difference in canister weight before use and after all contents were expelled.

Results: A total of 17,589 albuterol and 20,563 ICS/LABA MDIs were dispensed during the study. The total propellant weight led to CO2e emissions of 212 metric tons (MT) for albuterol MDIs and 506 MT for ICS/LABA MDIs. Including resource use and emissions from inhaler components led to an environmental impact that totaled 213 MT of CO2e for albuterol MDIs and 512.5 MT for ICS/LABA MDIs.

Conclusion: Our study emphasizes the necessity of integrating environmental stewardship into healthcare practices. By fostering awareness and initiating discussions on sustainable practices, particularly in the context of pharmacy operations, we can contribute to a more environmentally responsible healthcare system while continuing to meet the clinical needs of our patients.

净化空气:评估卫生系统中吸入器使用和相关温室气体排放。
免责声明:为了加快文章的发表,AJHP在接受稿件后将尽快在网上发布。被接受的稿件已经过同行评审和编辑,但在技术格式化和作者校对之前会在网上发布。这些手稿不是记录的最终版本,稍后将被最终文章(按照AJHP风格格式化并由作者校对)所取代。目的:从氟氯化碳向氢氟烷烃的过渡大大减少了与计量吸入器相关的温室气体排放。然而,与干粉吸入器(dpi)和软雾吸入器(SMIs)等其他替代品相比,HFAs仍具有较高的全球变暖潜能值(GWP)。这一转变对温室气体排放产生了重大影响,强调有必要评估通过计量吸入器给药对环境的影响。目的:本研究量化了我国卫生系统内mdi使用HFAs产生的温室气体排放量,以二氧化碳当量(CO2eq)表示。医疗保健系统包括13家医院,拥有2000多张床位,每年约有10万名患者入院。它还审查了与这些吸入器有关的包装材料的更广泛的环境影响。方法:回顾性分析沙丁胺醇和吸入皮质类固醇/长效β2激动剂(ICS/LABA) MDIs在1年期间的使用情况,评估其二氧化碳排放量及其包装对环境的影响。推进剂的总重量是通过计算使用前和所有内容物排出后的罐重差来确定的。结果:本研究共发放沙丁胺醇17589支,ICS/LABA MDIs 20563支。推进剂总重量导致沙丁胺醇计量吸入器的二氧化碳排放量为116公吨,ICS/LABA计量吸入器的二氧化碳排放量为506公吨。包括吸入器组件的资源使用和排放导致的环境影响,沙丁胺醇计量吸入器和ICS/LABA计量吸入器的二氧化碳当量合计为1.17亿吨和5.125亿吨。结论:本研究强调了将环境管理纳入医疗实践的必要性。通过培养对可持续实践的认识和发起讨论,特别是在药房运营的背景下,我们可以在继续满足患者临床需求的同时,为更环保的医疗保健系统做出贡献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.90
自引率
18.50%
发文量
341
审稿时长
3-8 weeks
期刊介绍: The American Journal of Health-System Pharmacy (AJHP) is the official publication of the American Society of Health-System Pharmacists (ASHP). It publishes peer-reviewed scientific papers on contemporary drug therapy and pharmacy practice innovations in hospitals and health systems. With a circulation of more than 43,000, AJHP is the most widely recognized and respected clinical pharmacy journal in the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信